Clinical Trial Update: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) [Phase 1]

View source ↗

Summary

This update reports results from a Phase 1 study evaluating subcutaneous TAK-079 added to standard-of-care regimens in adults with newly diagnosed multiple myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TAK-079

Snippet

Sponsor: Takeda | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED